Indication:
Remetiro (resmetirom) is indicated for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) accompanied by moderate to advanced liver fibrosis (stages F2 to F3 fibrosis), in conjunction with diet and exercise.

Mechanism of Action:
Resmetirom is a partial agonist of thyroid hormone receptor-beta (THR-β), which is predominantly expressed in the liver. Activation of THR-β reduces intrahepatic triglycerides without significant effects on thyroid hormone receptors in other tissues (e.g., heart, bone).

Dosage:

• Weight-based dosing:

• <100 kg body weight: 80 mg orally once daily.

• ≥100 kg body weight: 100 mg orally once daily.

• Administer once daily with or without food.

Storage Conditions:

• No special storage requirements (store at room temperature).

• Keep in original packaging to protect from moisture.

• Keep out of sight and reach of children.

• Do not use after the expiry date stated on the carton/blister/bottle.

Additional Notes:

• Not recommended for use in patients with decompensated cirrhosis (Child-Pugh Class B or C).

• Safety and efficacy in pediatric patients and NASH cirrhosis have not been established